Elite Pharmaceuticals, Inc. (OTCQB: ELTP) has filed a Current Report on Form 8-K dated November 12, 2026, announcing its financial results for the second quarter of fiscal year 2027, which ended September 30, 2026. The company reported consolidated revenues of $40.1 million for the three-month period. This figure represents an increase of $3.8 million, or approximately 10.4%, compared to the same period in the prior fiscal year.
The filing indicates that this revenue growth was primarily driven by increased sales from the Elite label amphetamine and naltrexone product lines. In terms of profitability, the company reported income from operations of $9.9 million for the quarter. This is an increase of $1.7 million, or approximately 21%, compared to the prior year's same period.
Net income attributable to common shareholders was reported at $17.3 million for the second quarter of fiscal year 2027. Elite Pharmaceuticals also disclosed that it will host a conference call on Friday, November 13, 2026, at 11:30 AM Eastern Standard Time to discuss these results and provide a general business update. Stockholder questions are to be submitted in advance of the call.
